Question 1

What did Cizzle Biotechnology Holdings say triggered its commercial launch activities in North America and the Caribbean on 12 June 2026?

Accepted Answer

Cizzle Bio’s commercial launch activities in North America/Caribbean by licencee Cizzle Bio were triggered by completion of partner roll-out agreements and laboratory partnerships.

Question 2

Where did sales begin for the CIZ1B lung cancer test after OmniHealth Diagnostics received CLIA certification?

Accepted Answer

Initial sales began at OmniHealth Diagnostics in Dallas after CLIA certification for the CIZ1B lung cancer laboratory-developed test.

Question 3

What did Cizzle Biotechnology Holdings report about the US CLIA accreditation milestone on 15 July 2026?

Accepted Answer

On 15 July 2026, Cizzle Bio reported CLIA accreditation enabling clinical use in the US, triggered by CLIA authorisation and the start of testing at OmniHealth Diagnostics and other partner labs.

Question 4

What laboratory agreement did BioBridge Global sign for Cizzle Biotechnology Holdings' CIZ1B test?

Accepted Answer

Cizzle said its North American licensing partner, Cizzle Bio, signed a laboratory agreement with BioBridge Global (San Antonio). BioBridge subsidiary BBG Advanced Therapies will offer the CIZ1B Biomarker Blood Test for Lung Cancer to licensed providers across South Texas after its validation is completed.

Question 5

When did OmniHealth Diagnostics in Dallas, Texas begin initial sales of Cizzle’s CIZ1B biomarker test?

Accepted Answer

OmniHealth Diagnostics began initial sales of Cizzle’s CIZ1B biomarker test on 16 June in the first half of 2026.

Question 6

What accreditation did Cizzle report that its CIZ1B biomarker test received for clinical use in the United States?

Accepted Answer

Cizzle reported that its CIZ1B biomarker test received CLIA accreditation for clinical use in the United States.

Timeline

Cizzle Biotechnology

Cizzle's US partner adds second lab for lung cancer test

Cizzle Biotechnology gains US accreditation for lung cancer test

Cizzle Biotechnology Holdings shares skyrocketed after US CLIA approval

Cizzle Biotechnology Holdings shares up on US patent grant

More in Medtech & Diagnostics

Smith+Nephew brings cartilage repair implant to Europe

Cambridge Cognition joins NHS study on earlier Alzheimer's diagnosis

Light Science trims revenue outlook amid regulatory delays

IXICO presents Parkinson's imaging research at European conference

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

GENinCode revenue halves as NHS cutbacks bite

Ondine partners with Mela Solutions to speed NHS Steriwave adoption

Abingdon Health lab wins ISO/IEC 17025 accreditation

CelLBxHealth revenues halve as turnaround cuts costs and sets 2026 growth target

Abingdon Health opens US manufacturing hub in Wisconsin

Ondine's Steriwave rolls out across five Ontario hospitals

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer